SECTION 1. SHORT TITLE.
This Act may be cited as the ‘‘Anabolic Steroid Con-
trol Act of 2004’’.
SEC. 2. INCREASED PENALTIES FOR ANABOLIC STEROID
OFFENSES NEAR SPORTS FACILITIES.
(a) IN GENERAL.—Part D of the Controlled Sub-
stances Act is amended by adding at the end the following:
ANABOLIC STEROID OFFENSES NEAR SPORTS FACILITIES
‘‘SEC. 424. (a) Whoever violates section 401(a)(1) or
section 416 by manufacturing, distributing, or possessing
with intent to distribute, an anabolic steroid near or at
a sports facility is subject to twice the maximum term of
imprisonment, maximum fine, and maximum term of su-
pervised release otherwise provided by section 401 for that
offense.
‘‘(b) As used in this section—
‘‘(1) the term ‘sports facility’ means real prop-
erty where athletic sports or athletic training takes
place, if such property is privately owned for com-
mercial purposes or if such property is publicly
owned, but does not include any real property de-
scribed in section 419;
‘‘(2) the term ‘near or at’ means in or on, or
within 1000 feet of; and
‘‘(3) the term ‘possessing with intent to dis-
tribute’ means possessing with the intent to dis-
tribute near or at a sports facility.’’.
(b) TABLE OF CONTENTS AMENDMENT.—The table
of contents for Comprehensive Drug Abuse Prevention
and Control Act of 1970 is amended by inserting after
the item relating to section 423 the following new item:
‘‘Sec. 424. Anabolic steroid offenses near sports facilities.’’.
SEC. 3. SENTENCING COMMISSION GUIDELINES.
The United States Sentencing Commission shall—
(1) review the Federal sentencing guidelines
with respect to offenses involving anabolic steroids;
(2) consider amending the Federal sentencing
guidelines to provide for increased penalties with re-
spect to offenses involving anabolic steroids in a
manner that reflects the seriousness of such offenses
and the need to deter anabolic steroid use; and
(3) take such other action that the Commission
considers necessary to carry out this section.
SEC. 4. AMENDMENTS TO THE CONTROLLED SUBSTANCES
ACT.
(a) DEFINITIONS.—Section 102 of the Controlled
Substances Act (21 U.S.C. 802) is amended—
(1) in paragraph (41)—
(A) by realigning the margin so as to align
with paragraph (40); and
(B) by striking subparagraph (A) and in-
serting the following:
‘‘(A) The term ‘anabolic steroid’ means any drug or
hormonal substance, chemically and pharmacologically re-
lated to testosterone (other than estrogens, progestins,
corticosteroids, 
and 
dehydroepiandrosterone), 
and
includes—
‘‘(i) androstanediol—
‘‘(I) 3β,17β-dihydroxy-5α-androstane; and
‘‘(II) 3α,17β-dihydroxy-5α-androstane;
‘‘(ii) 
androstanedione 
(5α-androstan-3,17-
dione);
‘‘(iii) androstenediol—
‘‘(I) 1-androstenediol (3β,17β-dihydroxy-
5α-androst-1-ene);
‘‘(II) 1-androstenediol (3α,17β-dihydroxy-
5α-androst-1-ene);
‘‘(III) 4-androstenediol (3β,17β-dihydroxy-
androst-4-ene); and
‘‘(IV) 5-androstenediol (3β,17β-dihydroxy-
androst-5-ene);
‘‘(iv) androstenedione—
‘‘(I) 1-androstenedione ([5α]-androst-1-en-
3,17-dione);
‘‘(II) 
4-androstenedione 
(androst-4-en-
3,17-dione); and
‘‘(III) 
5-androstenedione 
(androst-5-en-
3,17-dione);
‘‘(v) 
bolasterone 
(7α,17α-dimethyl-17β-
hydroxyandrost-4-en-3-one);
‘‘(vi) boldenone (17β-hydroxyandrost-1,4,-diene-
3-one);
‘‘(vii) 
calusterone 
(7β,17α-dimethyl-17β-
hydroxyandrost-4-en-3-one);
‘‘(viii) clostebol (4-chloro-17β-hydroxyandrost-4-
en-3-one);
‘‘(ix) dehydrochlormethyltestosterone (4-chloro-
17β-hydroxy-17α-methylandrost-1,4-dien-3-one);
‘‘(x) ∆1-dihydrotestosterone (also known as 1-
testosterone) (17β-hydroxy-5α-androst-1-en-3-one);
‘‘(xi) 
4-dihydrotestosterone 
(17β-hydroxy-
androstan-3-one);
‘‘(xii) drostanolone (17β-hydroxy-2α-methyl-5α-
androstan-3-one);
‘‘(xiii) ethylestrenol (17α-ethyl-17β-hydroxyestr-
4-ene);
‘‘(xiv) fluoxymesterone (9-fluoro-17α-methyl-
11β,17β-dihydroxyandrost-4-en-3-one);
‘‘(xv) 
formebolone 
(2-formyl-17α-methyl-
11α,17β-dihydroxyandrost-1,4-dien-3-one);
‘‘(xvi) 
furazabol 
(17α-methyl-17β-
hydroxyandrostano[2,3-c]-furazan);
‘‘(xvii) 13α-ethyl-17β-hydroxygon-4-en-3-one;
‘‘(xviii) 4-hydroxytestosterone (4,17β-dihydroxy-
androst-4-en-3-one);
‘‘(xix) 
4-hydroxy-19-nortestosterone 
(4,17β-
dihydroxy-estr-4-en-3-one);
‘‘(xx) mestanolone (17α-methyl-17β-hydroxy-
5α-androstan-3-one);
‘‘(xxi) 
mesterolone 
(1α-methyl-17β-hydroxy-
[5α]-androstan-3-one);
‘‘(xxii) 
methandienone 
(17α-methyl-17β-
hydroxyandrost-1,4-dien-3-one);
‘‘(xxiii) 
methandriol 
(17α-methyl-3β,17β-
dihydroxyandrost-5-ene);
‘‘(xxiv) methenolone (1-methyl-17β-hydroxy-5α-
androst-1-en-3-one);
‘‘(xxv) 
methyltestosterone 
(17α-methyl-17β-
hydroxyandrost-4-en-3-one);
‘‘(xxvi) 
mibolerone 
(7α,17α-dimethyl-17β-
hydroxyestr-4-en-3-one);
‘‘(xxvii) 17α-methyl-∆1-dihydrotestosterone (17
β-hydroxy-17α-methyl-5α-androst-1-en-3-one) (also
known as ‘17-α-methyl-1-testosterone’);
‘‘(xxviii) nandrolone (17β-hydroxyestr-4-en-3-
one);
‘‘(xxix) norandrostenediol—
‘‘(I) 19-nor-4-androstenediol (3β, 17β-
dihydroxyestr-4-ene);
‘‘(II) 19-nor-4-androstenediol (3α, 17β-
dihydroxyestr-4-ene);
‘‘(III) 19-nor-5-androstenediol (3β, 17β-
dihydroxyestr-5-ene); and
‘‘(IV) 19-nor-5-androstenediol (3α, 17β-
dihydroxyestr-5-ene);
‘‘(xxx) norandrostenedione—
‘‘(I) 19-nor-4-androstenedione (estr-4-en-
3,17-dione); and
‘‘(II) 19-nor-5-androstenedione (estr-5-en-
3,17-dione);
‘‘(xxxi) 
norbolethone 
(13β,17α-diethyl-17β-
hydroxygon-4-en-3-one);
‘‘(xxxii) norclostebol (4-chloro-17β-hydroxyestr-
4-en-3-one);
‘‘(xxxiii) 
norethandrolone 
(17α-ethyl-17β-
hydroxyestr-4-en-3-one);
‘‘(xxxiv) oxandrolone (17α-methyl-17β-hydroxy-
2-oxa-[5α]-androstan-3-one);
‘‘(xxxv) 
oxymesterone 
(17α-methyl-4,17β-
dihydroxyandrost-4-en-3-one);
‘‘(xxxvi) 
oxymetholone 
(17α-methyl-2-
hydroxymethylene-17β-hydroxy-[5α]-androstan-3-
one);
‘‘(xxxvii) stanozolol (17α-methyl-17β-hydroxy-
[5α]-androst-2-eno[3,2-c]-pyrazole);
‘‘(xxxviii) 
stenbolone 
(17β-hydroxy-2-methyl-
[5α]-androst-1-en-3-one);
‘‘(xxxix) testolactone (13-hydroxy-3-oxo-13,17-
secoandrosta-1,4-dien-17-oic acid lactone);
‘‘(xl) testosterone (17β-hydroxyandrost-4-en-3-
one);
‘‘(xli) tetrahydrogestrinone (13β,17α-diethyl-
17β-hydroxygon-4,9,11-trien-3-one);
‘‘(xlii) trenbolone (17β-hydroxyestr-4,9,11-trien-
3-one); and
‘‘(xliii) any salt, ester, or ether of a drug or
substance described in this paragraph;’’; and
(2) in paragraph (44), by inserting ‘‘anabolic
steroids,’’ after ‘‘marihuana,’’.
SEC. 5. REPORTING REQUIREMENT.
Not later than 2 years after the date of the enact-
ment of this Act, the Secretary of Health and Human
Services, in consultation with the Attorney General, shall
prepare and submit a report to the Judiciary Committee
of the House and Senate, and to the Committee on Energy
and Commerce of the House, evaluating the health risks
associated with dietary supplements not scheduled under
the amendments made by this Act which contain sub-
stances similar to those added to the list of controlled sub-
stances under those amendments. The report shall include
recommendations on whether such substances should be
regulated as anabolic steroids.
Passed the House of Representatives June 3, 2004.
Attest:
Clerk.
108TH CONGRESS
2D SESSION
H. R. 3866
AN ACT
To amend the Controlled Substances Act to provide
increased penalties for anabolic steroid offenses
near sports facilities, and for other purposes.